Recent Updates
Recently added Catalysts

AZD7687

Phase 1

Type 2 Diabetes | Small molecule | Metabolic |AstraZeneca PLC|Last Updated: Feb 13, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment36
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01217905Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687PHASE1 COMPLETED 36Nov 1, 2010Jul 1, 2011Feb 13, 20121 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Investigate the safety and tolerability of AZD7687 following administration of single and multiple doses
From screening period to follow-up visit 45 days (Maximum).
Secondary Endpoints
Evaluate the pharmacokinetics (PK) (plasma and urine) of AZD7687 and it´s glucuronic acid metabolite (AZ13128940) after single and multiple doses
Before dose and repeatedly to follow-up visit
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSINGLE_GROUP
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
1EXPERIMENTAL -
Interventions
NameTypeDescription
AZD7687DRUGOral suspension
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 45 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Suitable veins for cannulation or repeated venipuncture * Have a body mass index (BMI) between 19 and 35 kg/m2 and weigh at least 50 kg and no more than 90 kg * Male subjects should be willing to use barrier contraception ie, condoms with spermicide, from the first day of dosi...

Countries:United Kingdom
Unlock Eligibility Criteria